Download PDF
J Pediatr Infect Dis 2019; 14(03): 116-120
DOI: 10.1055/s-0038-1677484
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Waning Time of Maternally Derived Anti-Hepatitis A and Anti-Varicella Zoster Virus Antibodies

Zeliha Guzelkucuk
1   Department of Pediatrics, Gazi University School of Medicine, Ankara, Turkey
,
Aysu Duyan Camurdan
1   Department of Pediatrics, Gazi University School of Medicine, Ankara, Turkey
,
Ufuk Beyazova
1   Department of Pediatrics, Gazi University School of Medicine, Ankara, Turkey
,
Gulendam Bozdayı
2   Department of Microbiology, Gazi University School of Medicine, Ankara, Turkey
,
Fusun Civil
3   Department of Public Health, Gazi University School of Medicine, Ankara, Turkey
,
Aylin Altay Kocak
2   Department of Microbiology, Gazi University School of Medicine, Ankara, Turkey
› Author Affiliations Funding Gazi University Scientific Research Projects Committee (project code: 01/2011-103).
Further Information

Publication History

11 June 2018

04 December 2018

Publication Date:
09 January 2019 (online)

    Permissions and Reprints

Abstract

Objective The objective of this study was to investigate the persistence of maternally derived antibodies to hepatitis A (anti-HAV) and varicella zoster (anti-VZV) viruses to determine the optimal time of vaccination of infants.

Materials and Methods This study was conducted between 2011 and 2012 at the Gazi University Hospital. Blood samples were collected from healthy infants' cord blood and at 12th, 18th, and 24th months of age. Anti-HAV and anti-VZV immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies were measured by enzyme-linked immunosorbent assay kit in blood samples.

Results A total of 546 infants and children were included in the study; all had blood samples taken at four time points (at birth [cord blood], and at 12, 18, and 24 months). Anti-HAV IgG seropositivity rates in these samples were 77.3, 29.6, 14.8, and 17.7%, respectively (p < 0.05). Corresponding anti-VZV IgG seropositivity rates were 83.3, 21.5, 29.5, and 33.8%, respectively (p < 0.05).

Conclusion Anti-HAV and anti-VZV seropositivity rates were lowest at 18 and 12 months, respectively. We suggest that if VZV and hepatitis A vaccines were included in the national vaccination program after the age of 1 year, there should be little interference from passively acquired maternal antibodies.

Keywords

maternally derived antibody - hepatitis A - varicella zoster - vaccine

Authors' Contributions

Z.G. and A.D.C. conceived the study; A.D.C. and U.B. designed the study protocol; A.D.C. and Z.G. performed the clinical assessment; G.B. performed the immunoassays, F.C. performed the analysis and interpretation of these data. A.D.C. and Z.G. drafted the article; U.B. critically revised the article for intellectual content. All authors read and approved the final article. A.D.C. is the guarantor of the article.


Ethical Approval

This study was approved by the Ethical Committee of Gazi University Hospital (date/number: February 8, 2012/046).


 

  • References

  • 1 Fiore AE, Feinstone SM, Bell BP. Hepatitis A vaccines. In: Plotkin SA, Orenstein WA, Offit P. , eds. Vaccines, 5th ed. China: Saunders Elsevier Inc; 2008: 177-203
    Google Scholar
  • 2 Kanra G, Tezcan S, Badur S. ; Turkish National Study Team. Hepatitis A seroprevalence in a random sample of the Turkish population by simultaneous EPI cluster and comparison with surveys in Turkey. Turk J Pediatr 2002; 44 (03) 204-210
    PubMedGoogle Scholar
  • 3 Ceyhan M, Yildirim I, Kurt N. , et al. Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendations. J Viral Hepat 2008; 15 (02) (Suppl. 02) 69-72
    CrossrefPubMedGoogle Scholar
  • 4 Kurugol Z, Aslan A, Turkoglu E, Koturoglu G. Changing epidemiology of hepatitis A infection in Izmir, Turkey. Vaccine 2011; 29 (37) 6259-6261
    CrossrefPubMedGoogle Scholar
  • 5 Aydoğdu S, Ozgenç F, Yurtsever S, Akman SA, Tokat Y, Yağci RV. Our experience with fulminant hepatic failure in Turkish children: etiology and outcome. J Trop Pediatr 2003; 49 (06) 367-370
    CrossrefPubMedGoogle Scholar
  • 6 The Ministry of Health of Turkey Health Statistics Yearbook. 2006. Available at: www.saglik.gov.tr/TR/belge/1-2952/istatistik-yilliklari.html
    PubMed
  • 7 Kanra G, Tezcan S, Badur S. ; Turkish National Study Team. Varicella seroprevalence in a random sample of the Turkish population. Vaccine 2002; 20 (9-10): 1425-1428
    CrossrefPubMedGoogle Scholar
  • 8 Dinleyici EC, Kurugol Z, Turel O. , et al; VARICOMP Study Group. The epidemiology and economic impact of varicella-related hospitalizations in Turkey from 2008 to 2010: a nationwide survey during the pre-vaccine era (VARICOMP study). Eur J Pediatr 2012; 171 (05) 817-825
    CrossrefPubMedGoogle Scholar
  • 9 Kovarik J, Siegrist CA. Optimization of vaccine responses in early life: the role of delivery systems and immunomodulators. Immunol Cell Biol 1998; 76 (03) 222-236
    CrossrefPubMedGoogle Scholar
  • 10 Siegrist CA. The challenges of vaccine responses in early life: selected examples. J Comp Pathol 2007; 137 (Suppl. 01) S4-S9
    CrossrefPubMedGoogle Scholar
  • 11 Siegrist CA. Vaccine immunology. In: Plotkin S, Orenstein W, Offit P. , eds Vaccines. China: Saunders Elsevier Inc; 2008: 17-36
    CrossrefGoogle Scholar
  • 12 Palfi M, Selbing A. Placental transport of maternal immunoglobulin G. Am J Reprod Immunol 1998; 39 (01) 24-26
    CrossrefPubMedGoogle Scholar
  • 13 van den Berg JP, Westerbeek EA, van der Klis FR, Berbers GA, van Elburg RM. Transplacental transport of IgG antibodies to preterm infants: a review of the literature. Early Hum Dev 2011; 87 (02) 67-72
    CrossrefPubMedGoogle Scholar
  • 14 Leuridan E, Hens N, Hutse V, Aerts M, Van Damme P. Kinetics of maternal antibodies against rubella and varicella in infants. Vaccine 2011; 29 (11) 2222-2226
    CrossrefPubMedGoogle Scholar
  • 15 Brinkhof MW, Mayorga O, Bock J, Heininger U, Herzog C. Kinetics of maternally acquired anti-hepatitis A antibodies: prediction of waning based on maternal or cord blood antibody levels. Vaccine 2013; 31 (11) 1490-1495
    CrossrefPubMedGoogle Scholar
  • 16 Sharapov UM, Bulkow LR, Negus SE. , et al. Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up. Hepatology 2012; 56 (02) 516-522
    CrossrefPubMedGoogle Scholar
  • 17 Letson GW, Shapiro CN, Kuehn D. , et al. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. J Pediatr 2004; 144 (03) 327-332
    CrossrefPubMedGoogle Scholar
  • 18 Derya A, Necmi A, Emre A, Akgün Y. Decline of maternal hepatitis A antibodies during the first 2 years of life in infants born in Turkey. Am J Trop Med Hyg 2005; 73 (02) 457-459
    PubMedGoogle Scholar
  • 19 Linder N, Karetnyi Y, Gidony Y. , et al. Decline of hepatitis A antibodies during the first 7 months of life in full-term and preterm infants. Infection 1999; 27 (02) 128-131
    CrossrefPubMedGoogle Scholar
  • 20 Lieberman JM, Chang SJ, Partridge S. , et al. Kinetics of maternal hepatitis a antibody decay in infants: implications for vaccine use. Pediatr Infect Dis J 2002; 21 (04) 347-348
    CrossrefPubMedGoogle Scholar
  • 21 Heininger U, Desgrandchamps D, Schaad UB. Seroprevalence of varicella-zoster virus IgG antibodies in Swiss children during the first 16 months of age. Vaccine 2006; 24 (16) 3258-3260
    CrossrefPubMedGoogle Scholar
  • 22 Pinquier D, Gagneur A, Balu L. , et al. Prevalence of anti-varicella-zoster virus antibodies in French infants under 15 months of age. Clin Vaccine Immunol 2009; 16 (04) 484-487
    CrossrefPubMedGoogle Scholar
  • 23 WHO. Hepatitis A vaccines position paper. Weekly Epidemiol Rec 2000; 75: 38-44
    PubMedGoogle Scholar
  • 24 Republic of Turkey Ministry of Health, Turkey Public Health Agency, Immunisation Advisory Board Decision (Date/Number: August 15, 2012/5754, 25.01.2013/8078)
    PubMed
  • 25 Rozenbaum MH, van Hoek AJ, Vegter S, Postma MJ. Cost-effectiveness of varicella vaccination programs: an update of the literature. Expert Rev Vaccines 2008; 7 (06) 753-782
    CrossrefPubMedGoogle Scholar
  • 26 Ince OT, Yalçin SS, Yurdakök K, Ozmert EN. Hepatitis A seroprevalence among infants aged 12 months in Ankara. Turk J Pediatr 2011; 53 (01) 114-116
    PubMedGoogle Scholar
  • 27 Fiore AE, Shapiro CN, Sabin K. , et al. Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose. Pediatr Infect Dis J 2003; 22 (04) 354-359
    PubMedGoogle Scholar